New antibody combo could shield kids from rabies after bites
NCT ID NCT07327307
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 232 children under 18 who received a new antibody injection (zamerovimab and mazorelvimab) plus the rabies vaccine after a severe animal bite. Researchers track whether the children stay rabies-free for up to one year. The goal is to see if this combination prevents rabies effectively in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Zamerovimab and Mazorelvimab injection (antibodies) plus rabies vaccine
- What this could lead to
- If successful, this could confirm a new antibody treatment that, combined with the vaccine, prevents rabies after severe bites in children.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. Rabies is rare, so proving effectiveness is challenging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 232 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals under 18 years of age with category III rabies exposure who have received post-exposure prophylaxis (PEP) with Zamerovimab and Mazorelvimab Injection /other passive immunization products combined rabies vaccine in the real world
- Ages
-
0 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age under 18 years on the day of enrollment, regardless of gender, and able to provide legal proof of identity; 2. Individuals with WHO Category III rabies exposure, and the time from exposure to the initiation of Post-Exposure Prophylaxis (PEP) is \<7 days; 3. Have completed standardized wound management, injection of Zamerovimab and Mazorelvimab Injection /other passive immunization products, and the first dose of rabies vaccination within 24 hours prior to screening; 4. The volunteer's guardian voluntarily agrees to their participation in the study and signs the informed consent form. Specifically: for volunteers under 8 years old, the guardian signs the informed consent form with the child's assent fully respected; for volunteers aged 8-17, the guardian signs the informed consent form, and the minor volunteer signs the minor assent form; 5. Willing and able to comply with all study procedures, and is expected to be able to complete the full course of rabies vaccination and the 1-year follow-up as required (with no plans for long-term absence or relocation from the study area). Exclusion Criteria: 1. Based on inquiry, besides the current Category III rabies exposure, there is a history of bites by dogs, cats, mongooses, foxes, ferrets, skunks, bats, or raccoons within the past year; 2. Other conditions considered by the investigator as unsuitable for participation in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rabies post-exposure prophylaxis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Affiliated Nanhua Hospital, University of South China
RECRUITINGHengyang, Hunan, China
-
Hunan Provincial People's Hospital
RECRUITINGChangsha, Hunan, China
-
Jiangxi Provincial Chest Hospital
RECRUITINGNanchang, Jiangxi, China
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Shenzhen second people's hospital
RECRUITINGShenzhen, Guangdong, China
-
The University of Hong Kong - Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.